Washington, DC (November 25, 2020) – The President of the Global Alzheimer’s Platform Foundation (GAP), John Dwyer, issued the following statement regarding the Alzheimer’s Disease Data Initiative’s (ADDI) launch of the new Alzheimer’s disease data platform, AD Workbench.
“Congratulations on the launch of AD Workbench, by our colleagues at the Alzheimer’s Disease Data Initiative (ADDI). The publicly available data collected and analyzed on the AD Workbench platform will spur collaboration and expedite innovation. This open, easy to use, and inclusive resource will improve the ability of researchers to access data not previously available to them, and will lead to better treatments, and ultimately a cure for Alzheimer’s.
More data sharing and advanced analytics will catalyze life-changing breakthroughs in AD research. GAP is proud to be collaborating with ADDI on a study to investigate the correlation between blood and digital AD biomarkers and brain beta amyloid PET results. This study will reshape how research is conducted and speed the discovery of therapies. GAP is committed to adding the data from this study to the AD Workbench to help researchers identify which biomarkers are more useful for determining the presence of AD pathology.”
About the Global Alzheimer’s Platform Foundation (GAP)
The Global Alzheimer’s Platform Foundation® (GAP) is a patient-centric nonprofit dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Research centers across the US and Canada are part of the growing GAP Network (GAP-Net). GAP supports GAP-Net research centers by assisting with study start up and recruitment activities, promoting diversity in research studies, and offering national programs that champion brain health and the citizen scientists who make research possible.